Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Covid19: minimising risk to healthcare workers during aerosol producing respiratory therapy using an innovative constant flow canopy

Yochai Adir, Ori Segol, Dmitry Kompaniets, Hadas Ziso, Yechiam Yaffe, Irina Bergman, Erez Hassidov, Arieh Eden
European Respiratory Journal 2020; DOI: 10.1183/13993003.01017-2020
Yochai Adir
1Lady Davis Carmel Medical Center, Pulmonary Division, Haifa, Israel
2The Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ori Segol
1Lady Davis Carmel Medical Center, Pulmonary Division, Haifa, Israel
2The Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dmitry Kompaniets
1Lady Davis Carmel Medical Center, Pulmonary Division, Haifa, Israel
2The Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hadas Ziso
3Tamar Robotic LTD, Yagur, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yechiam Yaffe
4Yafit safety & environment, Mevasseret Zion, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina Bergman
1Lady Davis Carmel Medical Center, Pulmonary Division, Haifa, Israel
2The Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erez Hassidov
3Tamar Robotic LTD, Yagur, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arieh Eden
1Lady Davis Carmel Medical Center, Pulmonary Division, Haifa, Israel
2The Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

An innovative constant flow canopy enable non invasive respiratory support with minimal risk of HCW infection.

Noninvasive ventilation (NIV), continuous positive airway pressure (CPAP) and high flow nasal cannula (HFNC) can be used as the first line of treatment in COVID19 patients with respiratory failure, postponing and maybe even avoiding the need for intubation and mechanical ventilation [1]. Recent systematic review and meta-analysis demonstrated that HFNC reduces the need for intubation compared with conventional oxygen with no change of the death risk or ICU length of stay [2, 3], while no direct evidence supports the use of NIV due to a high failure rate [4]. However, when resources become limited with no option of invasive ventilation, the use of NIV may be justified. The major caveat of using noninvasive respiratory support in the face of the COVID19 pandemic is the generation of aerosols composed of small virus containing particles which may remain suspended in the air, with increased risk of health care workers (HCW) [7, 8]. The risk of aerosolization depends on many variables, including duration of use, flow velocity, mask leakage and patient coughing and cooperation.

At the current crisis with a limited number of ventilators and of negative pressure facilities we developed a novel way to reduce, and even eliminate, this exposure to potentially dangerous aerosol by using a constant flow canopy over the upper part of the patient bed, thus creating a confined area surrounding the patient in which non-invasive respiratory support can be safely used.

The system is composed of three parts: (i) A flexible plastic canopy that covers the upper part of the patient body, (ii) A fan filtering unit (FFU) composed of (a) a pre-filler in the air inlet (b) an electrical fan and a (c) HEPA filter in the air outlet (identical to those installed in biological cabinets). The filtering system is manufactured by LPA Cleanrooms & Laboratories Ltd, Israel. and (iii) an exhaust system (electrical fan) creating negative pressure and transfering the filtered air out to the open atmosphere. Each filtering unit can support up to 4 patients in parallel.

The polyethylene canopy serves as physical barrier between the HCW and the patient. The canopy should ensure maximum enclosure of patients upper body, however, a gap of 5–7 cm between the patients body and the canopy is designed enabling safe treatment. The system enables rapid acsess in case of an emergency from either the direction of the chest or head enabling rapid intubation or CPR.

The unit was evaluated by two techniques: 1. Face velocity and smoke direction: speed (m·s−1.) of air flowing perpendicular to the hood's opening inside the enclosure, and smoke flow in the direction of the enclosure back part (per US ASE/ASHRAE Standard 110). 2. Integrity test of the HEPA filtering unit, using photometery, to measure leakage of particles (0.3–0.5 um in size) through the filters. (per EN 12 469 - European Standard for Microbiological Safety Cabinets).

The results of our evaluation demonstrated that the average air flow velocity was 4.4 m·s−1 and the smoke clearly flows very fast into the back side of the canopy.The integrity results measured 0.0006% particles (maximum standard requiremet 0.01%).

In order to assess the satisfaction of the medical staff in the corona unit from the system we asked 9 physicians and nurses to fill a short 6 questions questioner. The overall impression score of the system was 9.1 (out of 10).

In summary this innovative negative pressure canopy allows us to administer NIV, CPAP or HFNC to patients with moderate to severe lung injury due to SARS-CoV-2 infection with minimal risk to HCW. The system has been installed in the Corona unit of the Carmel, Lady Davis MC, Haifa Israel.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

The constant flow canopy system.

Footnotes

  • Conflict of interest: I received personal fees for lecturing and/or consulting from Actelion, Boehringer Ingelheim, Teva, Bayer, GSK, Roche, Novartis, AstraZeneca, Kamada and UT Pharmaceuticals, and research grants from Actelion, Bayer, Boehringer Ingelheim and GSK

  • Conflict of interest: Dr. Segol has nothing to disclose.

  • Conflict of interest: Dr. Kompaniets has nothing to disclose.

  • Conflict of interest: Dr. Hassidov reports grants from The Israeli innovation authority have granted funds to Tamar Robotics LTD, such funds with the funds allocated by our investors where used to develop the system presented in this paper, during the conduct of the study; In addition, Dr. Hassidov has a patent U.S. Provisional Patent Application No. 63/001,562 - Israel Patent Application No. 273616 - Entitled: “PORTABLE PATIENT HOOD SYSTEM FOR PROTECTION OF MEDICAL STAFF AND OTHERS FROM INFECTIOUS DISEASE TRANSMISSION” pending, and a patent U.S. Provisional Patent Application No. 62/994,614 Entitled: “PORTABLE PATIENT HOOD SYSTEM FOR PROTECTION OF MEDICAL STAFF AND OTHERS FROM INFECTIOUS DISEASE TRANSMISSION” pending and I would like to state that: (1) i'm working in Tamar Robotics LTD that developed the system presented in the paper as a VP of R&D. (2) i'm the co-founder of Tamar Robotics LTD and i have holdings in the company (less then 6%). (3) Tamar Niv Breathing Solutions LTD may sale this product in the future and i will be receiving dividend or royalties if such sales will be made in the future.

  • Conflict of interest: Dr. Yaffe has nothing to disclose.

  • Conflict of interest: Dr. Bergman has nothing to disclose.

  • Conflict of interest: Dr. Hassidov reports grants from The Israeli innovation authority have granted funds to Tamar Robotics LTD, such funds with the funds allocated by our investors where used to develop the system presented in this paper, during the conduct of the study; In addition, Dr. Hassidov has a patent U.S. Provisional Patent Application No. 63/001,562 - Israel Patent Application No. 273616 - Entitled: “PORTABLE PATIENT HOOD SYSTEM FOR PROTECTION OF MEDICAL STAFF AND OTHERS FROM INFECTIOUS DISEASE TRANSMISSION” pending, and a patent U.S. Provisional Patent Application No. 62/994,614 Entitled: “PORTABLE PATIENT HOOD SYSTEM FOR PROTECTION OF MEDICAL STAFF AND OTHERS FROM INFECTIOUS DISEASE TRANSMISSION” pending and I would like to state that: (1) i'm working in Tamar Robotics LTD that developed the system presented in the paper as a part time job. (2) My brother is Noam Hassidov the CEO of Tamar Robotics LTD. (3) I'm a 5th year student in the Bar Illan medical school in israel. (4) I work once a week in the ER of Carmel medical Center as a physician assistance. (5) I don't have any holdings in Tamar Robotics or any other companies related to the system presented in this paper. (6) Tamar Niv Breathing Solutions LTD may sale this product in the future.

  • Conflict of interest: Dr. Eden has nothing to disclose.

  • Received April 4, 2020.
  • Accepted April 9, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

Reference

  1. ↵
    1. Critical care committee of Chinese Association of Chest Physician; Respiratory and critical care group of Chinese Thoracic Society; Respiratory care group of Chinese Thoracic Society
    . [Conventional respiratory support therapy for Severe Acute Respiratory Infections (SARI): Clinical indications and nosocomial infection prevention and control]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: 189–194. doi:10.3760/cma.j.issn.1001-0939.2020.03.010
    OpenUrl
  2. ↵
    1. Ni YN,
    2. Luo J,
    3. Yu H, et al.
    The effect of high flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. Am J Emerg Med 2018; 36: 226–233. doi:10.1016/j.ajem.2017.07.083
    OpenUrl
  3. ↵
    1. Rochwerg B,
    2. Granton D,
    3. Wang DX, et al.
    High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and metanalysis. Intensive Care Med 2019; 45: 563–572. doi:10.1007/s00134-019-05658-2
    OpenUrl
  4. ↵
    1. Esquinas AM,
    2. Egbert Pravinkumar S,
    3. Scala R, et al.
    International noninvasive mechanical ventilation in high-risk pulmonary infections: a clinical review. Eur Respir Rev 2014; 23: 427–438. doi:10.1183/09059180.00009413
    OpenUrlAbstract/FREE Full Text
    1. Wax RS,
    2. Christian MD
    . Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anaesth 2020. doi:10.1007/s12630-020-01591-x
    1. Guan L,
    2. Zhou L,
    3. Zhang J, et al.
    More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. Eur Respir J 2020; 55: 2000352. doi:10.1183/13993003.00352-2020
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 59 Issue 6 Table of Contents
European Respiratory Journal: 59 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Covid19: minimising risk to healthcare workers during aerosol producing respiratory therapy using an innovative constant flow canopy
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Covid19: minimising risk to healthcare workers during aerosol producing respiratory therapy using an innovative constant flow canopy
Yochai Adir, Ori Segol, Dmitry Kompaniets, Hadas Ziso, Yechiam Yaffe, Irina Bergman, Erez Hassidov, Arieh Eden
European Respiratory Journal Jan 2020, 2001017; DOI: 10.1183/13993003.01017-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Covid19: minimising risk to healthcare workers during aerosol producing respiratory therapy using an innovative constant flow canopy
Yochai Adir, Ori Segol, Dmitry Kompaniets, Hadas Ziso, Yechiam Yaffe, Irina Bergman, Erez Hassidov, Arieh Eden
European Respiratory Journal Jan 2020, 2001017; DOI: 10.1183/13993003.01017-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • Reference
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects
  • Normative multiple breath washout data in school-aged children corrected for sensor error
  • Screening for pulmonary veno-occlusive disease in heterozygous EIF2AK4 variant carriers
Show more Research letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society